Fresenius SE & Co. KGaA is a global leader in healthcare, committed to improving patient care and fulfilling unmet medical needs through innovative solutions. With a robust portfolio that includes products and services focused on a spectrum of medical areas, Fresenius plays a pivotal role in global health.
Fresenius is at the forefront of incorporating innovative therapies such as CAR-T cell therapy and immunotherapies, enhancing treatment options for diseases like cancer. The company employs advanced cell processing systems like Lovo and Cue, revolutionizing the administration of these groundbreaking therapies.
This year marks a significant milestone for Fresenius, celebrating 50 years of its renowned Fresubin enteral nutrition brand. The company continues to experience strong revenue growth, exemplified by its robust financial performance in 2025, where it raised its full-year revenue guidance.
Investors are encouraged by Fresenius' consistent performance, highlighted during the recent Annual General Meeting (AGM). With a strong focus on its #FutureFresenius strategy, the company aims to enhance its core businesses while maintaining a commitment to innovation and quality healthcare solutions.
Fresenius SE & Co. KGaA stands as a beacon of healthcare innovation and sustainability. With a dedicated workforce of over 176,000 employees and an expansive array of products and services, Fresenius is well-positioned to continue its mission of enhancing patient lives worldwide.